| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,702 |
7,323 |
$582K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,797 |
2,296 |
$100K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
3,829 |
3,401 |
$97K |
| 99215 |
Prolong outpt/office vis |
1,282 |
1,079 |
$46K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
985 |
901 |
$29K |
| 36415 |
Collection of venous blood by venipuncture |
4,029 |
3,415 |
$4K |
| G0511 |
Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month |
161 |
159 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
67 |
43 |
$2K |
| 99307 |
|
96 |
94 |
$2K |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
285 |
234 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
42 |
40 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,517 |
1,283 |
$874.61 |
| 0012A |
|
40 |
40 |
$741.09 |
| 99318 |
|
15 |
14 |
$590.05 |
| 0011A |
|
44 |
44 |
$582.75 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
277 |
185 |
$486.33 |
| 99310 |
Prolong nursin fac eval 15m |
13 |
13 |
$397.60 |
| 81001 |
|
17 |
12 |
$218.18 |
| G0247 |
Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include, the local care of superficial wounds (i.e. superficial to muscle and fascia) and at least the following if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails |
120 |
117 |
$171.30 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
12 |
12 |
$170.80 |
| 0001A |
|
14 |
14 |
$143.48 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
477 |
344 |
$77.60 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
55 |
50 |
$69.89 |
| G0246 |
Follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education |
119 |
116 |
$0.00 |
| 87634 |
|
96 |
73 |
$0.00 |
| 90715 |
|
12 |
12 |
$0.00 |
| 3078F |
|
70 |
67 |
$0.00 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
43 |
38 |
$0.00 |
| 3077F |
|
54 |
48 |
$0.00 |
| 3008F |
|
838 |
710 |
$0.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
295 |
266 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
324 |
285 |
$0.00 |
| 3074F |
|
29 |
29 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
13 |
13 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
14 |
14 |
$0.00 |
| 3079F |
|
16 |
15 |
$0.00 |
| 3075F |
|
12 |
12 |
$0.00 |